---
title: "Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296267429.md"
description: "Eli Lilly & Co. (LLY) shares rose 3.60% to $1,225.73 on Tuesday, outperforming competitors like Johnson & Johnson and Pfizer during a broader market decline. This marks the second consecutive day of gains for LLY, which remains just below its 52-week high. Trading volume was lower than the 50-day average."
datetime: "2026-08-18T20:31:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296267429.md)
  - [en](https://longbridge.com/en/news/296267429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296267429.md)
generator: "portal-rs"
---

# Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Eli Lilly & Co. (LLY) advanced 3.60% to $1,225.73 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.69% to 7,691.76 and Dow Jones Industrial Average falling 0.22% to 53,343.40.

This was the stock's second consecutive day of gains.

Eli Lilly & Co. closed 1.90% below its 52-week high of $1,249.45, which the company reached on July 7th.

The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 3.33% to $271.11, Pfizer Inc. (PFE) rose 1.41% to $27.25, and AbbVie Inc. (ABBV) rose 3.43% to $258.92.

Trading volume (2.4 M) remained 471,005 below its 50-day average volume of 2.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 18, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

08-18-26 1631ET

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Eli Lilly and Company $LLY Shares Purchased by Canada Pension Plan Investment Board](https://longbridge.com/en/news/297479625.md)
- [Evolve Private Wealth LLC Lowers Stock Holdings in Eli Lilly and Company $LLY](https://longbridge.com/en/news/297282696.md)
- [Is Eli Lilly Stock Outperforming the Dow?](https://longbridge.com/en/news/297309786.md)
- [Lilly's $9.94 Billion Mounjaro Franchise Wins a Heart-Risk Label](https://longbridge.com/en/news/297356212.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**